Aardvark Therapeutics, Inc. (AARD)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet
The mean of analysts' price targets for Aardvark Therapeutics, Inc. (AARD) points to an 180.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Biotechs Highlight 6 Stocks Insiders Are Buying Now
Biotech companies saw the most notable insider purchases of the past week, including at the latest of the recent handful of biotech initial public offerings.
U.S. IPO Weekly Recap: Big Listings Post Mixed Results In Busy 7 IPO Week
Seven IPOs and three SPACs were listed this week. Seven IPOs and four SPACs submitted initial filings. Some small IPOs are tentatively scheduled for the short holiday week ahead.
Aardvark Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 20 | $75.4 | $122.27 | $46.87 | 62.16% |
 Joseph Castro Nuveen LLC | 15,312 | $200,970.09 | $96,159.36 | -$104,810.73 | -52.15% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 2 | $7.54 | $13.21 | $5.67 | 75.2% |
 Li Peng China Universal Asset Management Co. Ltd. | 3,864 | $47,776.56 | $25,695.6 | -$22,080.96 | -46.22% |
 Kevin Kroskey True Wealth Design LLC | 49 | $185 | $310.17 | $125.17 | 67.66% |
Aardvark Therapeutics, Inc. (AARD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Aardvark Therapeutics, Inc. ever had a stock split?
Aardvark Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Tien-Li Lee CEO | NASDAQ (NGS) Exchange | 002942100 CUSIP |
| US Country | 40 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative small-molecule therapeutics aimed at activating innate homeostatic pathways for the treatment of various metabolic diseases. Founded in 2017, the company is advancing its lead product candidate, ARD-101, currently undergoing Phase III clinical trials for addressing hyperphagia in patients with Prader-Willi Syndrome. Additionally, ARD-101 is in Phase II trials for treating hyperphagia linked to acquired hypothalamic obesity due to treatment methods for craniopharyngioma, involving either surgery or radiation therapies. Aardvark Therapeutics is also in the early stages of developing ARD-201, which is presently undergoing Phase I clinical trials targeting obesity management.
Products and Services
- ARD-101:
This is an oral gut-restricted small-molecule agonist that activates specific bitter taste receptors found in the gut lumen. ARD-101 is being studied in Phase III clinical trials for its efficacy in treating hyperphagia associated with Prader-Willi Syndrome. Moreover, it is in Phase II clinical trials targeting hyperphagia stemming from acquired hypothalamic obesity, a condition observed in individuals following treatment for craniopharyngioma through surgical or radiation means.
- ARD-201:
Currently in Phase I clinical trials, ARD-201 represents Aardvark Therapeutics' efforts in developing a therapeutic for obesity. While still early in its development, ARD-201 aims to provide a viable treatment option for individuals struggling with obesity, contributing to Aardvark's mission of addressing metabolic diseases through innovative pharmacological strategies.
